OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Huppert on the Implications of SERENA-6 for Second-Line Treatment Strategies in HR+ Breast Cancer

July 29th 2025

Laura A. Huppert, MD, discusses how the approval of the SERENA-6 regimen could affect second-line treatment decision-making in HR-positive breast cancer.

Dr Kamdar on Optimizing Patient Monitoring After Liso-Cel in MCL

July 29th 2025

Manali Kamdar, MD, discusses the rationale for optimizing monitoring after the treatment of liso-cel in patients with mantle cell lymphoma.

Dr Reckamp on the Future Implications of the PRAGMATICA-LUNG Trial in Lung Cancer

July 26th 2025

Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.

Dr Das on Updates to the Standard First-Line Treatment Paradigm for ES-SCLC

July 26th 2025

Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.

Dr Landgren on Considerations Surrounding the Current Treatment Paradigm for Smoldering Multiple Myeloma

July 26th 2025

C. Ola Landgren, MD, PhD, discusses the current treatment paradigm for patients with smoldering multiple myeloma.

Dr Danilov on Considerations in Frontline Treatment Selection for CLL

July 26th 2025

Alexey Danilov, MD, PhD, discusses frontline treatment selection for chronic lymphocytic leukemia.

Dr Jänne on Second-Line Treatment Evolutions in EGFR-Mutated NSCLC

July 25th 2025

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

Dr Mok on Choosing Between First-Line Therapies for BRAF-Mutant NSCLC

July 25th 2025

Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.

Dr Patel on the p53 IHC Positivity as Potential Surrogate for Multi-Hit TP53 Mutations in MDS and AML

July 25th 2025

Shyam A. Patel, MD, PhD, discusses the threshold of p53 IHC positivity best correlating with multi-hit TP53 mutational status in MDS and AML.

Dr Gerber on the Benefits of p53 IHC Testing for Identifying TP53-Mutant MDS and AML in Underserved Regions

July 25th 2025

Jonathan M. Gerber, MD, discusses the potential implementation of p53 IHC testing for MDS and AML in regions with limited access to NGS.

Dr Mewawalla on the Real-World Roles of Cilta-Cel and Ide-Cel in R/R Myeloma

July 24th 2025

Prerna Mewawalla, MD, explains the roles of cilta-cel and ide-cel in clinical practice for the treatment of relapsed/refractory multiple myeloma.

Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC

July 24th 2025

Jorge Nieva, MD, discusses matched-adjusted indirect comparison data evaluating crizotinib vs alectinib, brigatinib, and lorlatinib in ALK-positive NSCLC.

Dr Patel on Toxicities Associated With Immunotherapy-Based Combinations in NSCLC

July 23rd 2025

Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.

Dr McCann on the Standard of Care for Managing ER+/HER2– Advanced Breast Cancer

July 23rd 2025

Kelly E. McCann, MD, PhD, details the current standard of care and novel approaches for the treatment of ER-positive, HER2-negative advanced breast cancer.

Dr Khan on the Role of Zanubrutinib in the Current CLL Treatment Paradigm

July 23rd 2025

Cyrus M. Khan, MD, discusses how zanubrutinib fits into the current treatment paradigm in chronic lymphocytic leukemia.

Dr Kuerer on the Rationale for Eliminating Surgery in Select Patients With HER2+ or Triple-Negative Breast Cancer

July 23rd 2025

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses eliminating surgery for select patients with a pCR after neoadjuvant therapy for early breast cancer.

Dr Shum on Evolving First-Line Treatment Approaches for EGFR-Mutant NSCLC

July 23rd 2025

Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.

Dr Donington on the Evolving Use of Perioperative Nivolumab in Resectable NSCLC

July 22nd 2025

Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.

Dr Luminari on the Safety Profile of Odronextamab in Relapsed/Refractory Follicular Lymphoma

July 22nd 2025

Stefano Luminari, MD, details the safety profile of odronextamab for the treatment of patients with relapsed/refractory follicular lymphoma.

Dr McKay on the Safety of Olaparib and Radium-223 in mCRPC With Bone Metastases

July 22nd 2025

Rana R. McKay, MD, FASCO, discusses the safety profiles of olaparib plus radium-223 vs radium-223 monotherapy in mCRPC.